Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010010 · ClinicalTrials.gov registry record · Phase 2
Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00010010: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT00010010 is a Phase 2 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00010010, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who have metastatic breast cancer that has not responded to previous tamoxifen.
Interventions
- DRUG exemestane
- DRUG goserelin acetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Phase | Phase 2 |
What the finished NCT00010010 record still lists
NCT00010010 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which exemestane is the first listed.
NCT00010010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00010010 about?
NCT00010010 is a clinical study titled "Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane plus goserelin may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of exemestane and goserelin in treating premenopausal women who hav...
What is the current status of trial NCT00010010?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06.
What interventions are being tested in trial NCT00010010?
The interventions under investigation include: exemestane (DRUG), goserelin acetate (DRUG).
Who is sponsoring clinical trial NCT00010010?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia